Baseline Pathological Liver Function Tests in Patients With Psoriasis Support the Indication for Systemic Therapy Rather Than Being a Reason Against It: A Real-World Analysis DOI Creative Commons
Frederik Krefting,

Christopher M. Scheib,

Sven Benson

et al.

Psoriasis Targets and Therapy, Journal Year: 2025, Volume and Issue: Volume 15, P. 29 - 44

Published: Feb. 28, 2025

Modern systemic therapies offer a high probability of significant improvement for psoriasis. However, elevated liver function tests (LFTs) may cause physicians to be reluctant initiate treatment. Especially considering the already increased risk disease in patients with psoriasis, clinicians are often concerned about potential further damage caused by therapies. The aim this study was provide real-world evidence address issue. This retrospectively analyzed treatment courses N = 278 psoriasis who received anti-psoriatic therapy secukinumab, ixekizumab, adalimumab, or apremilast clinical routine. cohort divided into two subgroups based on normal LFTs prior start therapy. AST, ALT, and GGT levels as well Fibrosis-4 score (FIB-4) were measured at baseline, after 3 months, 6 months subgroup had higher mean PASI (Psoriasis Area Severity Index), more likely male, prevalence metabolic syndrome comorbidities compared LFTs. During follow-up period, there no changes FIB-4 baseline. In group initially LFTs, all decreased significantly over time, whereas scores demonstrated change. Drug survival, discontinuation rates, PASI-75 response did not differ between subgroups. provides real world that does present general risk, but rather an opportunity

Language: Английский

Baseline Pathological Liver Function Tests in Patients With Psoriasis Support the Indication for Systemic Therapy Rather Than Being a Reason Against It: A Real-World Analysis DOI Creative Commons
Frederik Krefting,

Christopher M. Scheib,

Sven Benson

et al.

Psoriasis Targets and Therapy, Journal Year: 2025, Volume and Issue: Volume 15, P. 29 - 44

Published: Feb. 28, 2025

Modern systemic therapies offer a high probability of significant improvement for psoriasis. However, elevated liver function tests (LFTs) may cause physicians to be reluctant initiate treatment. Especially considering the already increased risk disease in patients with psoriasis, clinicians are often concerned about potential further damage caused by therapies. The aim this study was provide real-world evidence address issue. This retrospectively analyzed treatment courses N = 278 psoriasis who received anti-psoriatic therapy secukinumab, ixekizumab, adalimumab, or apremilast clinical routine. cohort divided into two subgroups based on normal LFTs prior start therapy. AST, ALT, and GGT levels as well Fibrosis-4 score (FIB-4) were measured at baseline, after 3 months, 6 months subgroup had higher mean PASI (Psoriasis Area Severity Index), more likely male, prevalence metabolic syndrome comorbidities compared LFTs. During follow-up period, there no changes FIB-4 baseline. In group initially LFTs, all decreased significantly over time, whereas scores demonstrated change. Drug survival, discontinuation rates, PASI-75 response did not differ between subgroups. provides real world that does present general risk, but rather an opportunity

Language: Английский

Citations

0